Corbus Q2 Loss Deepens on Higher R&D Spend; Cash Runway Extended Through Mid-2027
CRBP sits 36% above its 52-week low of $7.12 on light trading volume (0.3× avg).
Summary
Corbus reported a wider Q2 net loss of $35.0M as R&D costs doubled, including a $10M milestone payment for CRB-701. Cash runway extends at least 12 months, but ongoing ATM dilution and a new 10b5-1 plan by a director add overhang ahead of key clinical data readouts.
Key Events · Earnings and Guidance · CRBP
-
Q2 Net Loss Widens
Net loss of $35.0M ($1.81/share) vs $17.7M ($1.44/share) in Q2 2025, driven by a $10M milestone payment for CRB-701 and higher clinical costs.
-
Cash Runway Extended
Cash, equivalents, and investments of $117.9M at June 30, 2026, expected to fund operations for at least 12 months.
-
ATM Dilution Continues
894,044 shares sold under the ATM in Q2 for $9.1M net proceeds; post-quarter, another 738,707 shares sold for $6.7M, with $52.8M remaining capacity.
-
Director Adopts 10b5-1 Plan
Director Yong Ben adopted a Rule 10b5-1 plan on June 12, 2026, for the sale of up to 7,583 shares beginning September 14, 2026.
Analysis · CRBP · Life Sciences
Operating cash burn reached $55.2M in the first half of 2026, fueled by a $10M milestone payment for lead oncology asset CRB-701 and expanded clinical trials. Management ended Q2 with $117.9M in cash and investments, which it says funds operations for at least 12 months. Dilution continues via the ATM — 894,044 shares sold in Q2 for $9.1M, and another 738,707 shares sold post-quarter for $6.7M. The widening loss and ongoing ATM sales are offset by a clear clinical catalyst: the FDA has cleared the TEMPO-1 registrational study for CRB-701, with enrollment expected in September 2026.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $9.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $180.5M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.